Verrica Pharmaceuticals KOL Event: Discussing the Approval of YCANTH™ (Cantharidin) Topical Solution for the Treatment of Molluscum
About The Event
Join us for a virtual KOL event with Verrica Pharmaceuticals, featuring Mark Kaufmann, MD (Advanced Dermatology, Miami), Michael Cameron, MD (Cameron Dermatology; Department of Dermatology, Mount Sinai, NY), and Mercedes Gonzalez, MD (Pediatric Dermatology of Miami) who will discuss the unmet medical need for patients suffering from molluscum contagiosum (molluscum), a highly contagious viral skin disease that affects approximately six million people — primarily children — in the United States.
The event will focus on the recent approval of YCANTH™ (VP-102) as the only product approved by the FDA to treat molluscum in adult and pediatric patients two years of age and older. Molluscum is caused by a pox virus that produces distinctive raised, skin-toned-to-pink-colored lesions that can cause pain, inflammation, itching and bacterial infection. It is easily transmitted through direct skin-to-skin contact or through fomites and can spread to other parts of the body or to other people, including siblings. Without treatment, molluscum can last for an average of 13 months, and in some cases, up to five years.
A live question and answer session will follow the formal presentation.
See Important Safety Information at the end of this invitation and full Prescribing Information at YCANTHPro.com.